Zevra initiated with Outperform into transformational 2024 at William Blair

William Blair initiated coverage of Zevra Therapeutics with an Outperform rating and $13 fair value estimate. Over the past 12 months, he new management has been transforming Zevra into a fully integrated biotechnology company with a “nice mix” of marketed products and late- stage assets targeting rare diseases, the analyst tells investors in a research note. The firm says Zevra is set up for a transformational 2024. It expects the company to execute on the commercial launches of two products and says that while they may not become blockbusters, both approved products will “move the needle.”